US20090087489A1 - Imatinib compositions - Google Patents
Imatinib compositions Download PDFInfo
- Publication number
- US20090087489A1 US20090087489A1 US12/238,314 US23831408A US2009087489A1 US 20090087489 A1 US20090087489 A1 US 20090087489A1 US 23831408 A US23831408 A US 23831408A US 2009087489 A1 US2009087489 A1 US 2009087489A1
- Authority
- US
- United States
- Prior art keywords
- pharmaceutical composition
- imatinib mesylate
- tablet
- imatinib
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 239000005517 L01XE01 - Imatinib Substances 0.000 title claims abstract description 25
- 229960002411 imatinib Drugs 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims description 53
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 17
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 45
- 229960003685 imatinib mesylate Drugs 0.000 claims description 41
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 19
- 229960000913 crospovidone Drugs 0.000 claims description 13
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 13
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 238000007908 dry granulation Methods 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 238000007907 direct compression Methods 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 8
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 8
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 7
- 229960001021 lactose monohydrate Drugs 0.000 claims description 7
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 4
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 229940078495 calcium phosphate dibasic Drugs 0.000 claims description 2
- 238000005056 compaction Methods 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 238000001144 powder X-ray diffraction data Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- -1 Starlac Chemical compound 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 229940033134 talc Drugs 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- 229920003084 Avicel® PH-102 Polymers 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 235000019759 Maize starch Nutrition 0.000 description 4
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 229920003072 Plasdone™ povidone Polymers 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 229920003124 powdered cellulose Polymers 0.000 description 3
- 235000019814 powdered cellulose Nutrition 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004097 EU approved flavor enhancer Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 238000005004 MAS NMR spectroscopy Methods 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical group CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000009491 slugging Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920003085 Kollidon® CL Polymers 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229910002054 SYLOID® 244 FP SILICA Inorganic materials 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005384 cross polarization magic-angle spinning Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- Form X is characterized by data selected from the group consisting of: a powder XRD pattern with peaks at about 6.0, 8.6, 11.4, 14.2, 18.3 ⁇ 0.2 degrees two-theta; a powder XRD pattern having peaks at about: 6.0, 8.6, 10.2, 11.4, 14.2, 18.3 ⁇ 0.2 degrees two-theta; a powder XRD pattern having at least five peaks selected from the list consisting of peaks at about: 6.0, 8.6, 10.2, 11.4, 14.2, 17.8, 18.3, 21.6, 22.4, 23.6, 24.8 ⁇ 0.2 degrees two-theta; a solid-state 13 C NMR spectrum with signals at about 159.9, 158.2 and 153.4 ⁇ 0.2 ppm; a solid-state 13 C NMR spectrum having chemical shift differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of about 51.5, 49.8, and 45.0 ⁇ 0.1 ppm.
- the present invention also provides processes for preparing a pharmaceutical composition, preferably a tablet, containing imatinib or a pharmaceutical acceptable salt thereof, preferably imatinib mesylate in an amount of about 23-29% w/w, preferably of 25-29% w/w, more preferably of about 28-29% w/w.
- EUDRAGIT® potassium chloride
- powdered cellulose sodium chloride
- sorbitol talc
- diluents are selected from the group consisting of: Mannitol, calcium carbonate, Starlac, lactose, and di-basic calcium phosphate, most preferably the diluent is Starlac (82-88% Lactose monohydrate and 12-18% Maize starch).
- Solid pharmaceutical compositions that are compacted into a dosage form like a tablet can include excipients whose functions include helping to bind the active ingredient and other excipients together after compression.
- Binders for solid pharmaceutical compositions include at least one of acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. KLUCEL®), hydroxypropyl methyl cellulose (e.g.
- METHOCEL® liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. KOLLIDON®, PLASDONE®), pregelatinized starch, sodium alginate, or starch. More preferably the binders are selected from hydroxypropylcellulose, povidone (e.g. KOLLIDON®, PLASDONE®), or starch, most preferably the binder is povidone (e.g. KOLLIDON®, PLASDONE®).
- Glidants can be added to improve the flow properties of non-compacted solid composition and improve the accuracy of dosing.
- Excipients that can function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, and/or tribasic calcium phosphate. Most preferably the glidants are selected from talc, colloidal silicon dioxide, silicone dioxide NF most preferably the glidants is silicon dioxide NF.
- a dosage form such as a tablet is made by compaction of a powdered composition
- the composition is subjected to pressure from a punch and dye.
- Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and dye, which can cause the product to have pitting and other surface irregularities.
- a lubricant can be added to the composition to reduce adhesion and ease release of the product form the dye.
- Lubricants include, but are not limited to, magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and/or zinc stearate.
- the lubricants are selected from the group consisting of: sodium stearyl fumarate, magnesium stearate and talc.
- the lubricants are selected from the group consisting of magnesium stearate, sodium stearyl fumarate and a mixture thereof.
- Flavoring agents and flavor enhancers make the dosage form more palatable to the patient.
- Common flavoring agents and flavor enhancers for pharmaceutical products that can be included in the composition of the present invention include, but are not limited to, maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, or tartaric acid.
- Solid compositions can also be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.
- the tablets in accordance with the present invention comprise; from about 23% to 29% w/w, more preferably from about 25% to about 29% w/w, imatinib mesylate; from 10 to 60% w/w, more preferably from about 25% to about 60% w/w, of a diluent, filler or bulking agent, preferably lactose, more preferably starlac (82-88% Lactose monohydrate and 12-18% Maize starch); from 4 to 30% w/w, more preferably from about 10% to about 25% w/w, of a disintegrant, preferably crospovidone; from 0.2 to 5% w/w of a glidant, preferably silicon dioxide; and from 0.1 to 4% w/w, more preferably from about 0.5% to about 2% w/w, of a lubricant, preferably selected from magnesium stearate or sodium stearyl fumurate or the mixture thereof.
- a diluent, filler or bulking agent
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/238,314 US20090087489A1 (en) | 2007-09-25 | 2008-09-25 | Imatinib compositions |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99532107P | 2007-09-25 | 2007-09-25 | |
US99565107P | 2007-09-26 | 2007-09-26 | |
US12/238,314 US20090087489A1 (en) | 2007-09-25 | 2008-09-25 | Imatinib compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090087489A1 true US20090087489A1 (en) | 2009-04-02 |
Family
ID=40070888
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/238,314 Abandoned US20090087489A1 (en) | 2007-09-25 | 2008-09-25 | Imatinib compositions |
US12/238,328 Active 2031-03-09 US8414918B2 (en) | 2007-09-25 | 2008-09-25 | Stable imatinib compositions |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/238,328 Active 2031-03-09 US8414918B2 (en) | 2007-09-25 | 2008-09-25 | Stable imatinib compositions |
Country Status (9)
Country | Link |
---|---|
US (2) | US20090087489A1 (ru) |
EP (2) | EP2081556A1 (ru) |
JP (2) | JP2010540465A (ru) |
KR (1) | KR101041203B1 (ru) |
BR (1) | BRPI0817946A2 (ru) |
CA (1) | CA2700844A1 (ru) |
MX (1) | MX2010003200A (ru) |
RU (1) | RU2470641C2 (ru) |
WO (2) | WO2009042809A1 (ru) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011160798A1 (en) * | 2010-06-21 | 2011-12-29 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof |
WO2012087256A2 (en) * | 2010-12-20 | 2012-06-28 | Mahmut Bilgic | Pharmaceutical capsule formulations |
WO2017078647A1 (en) | 2015-11-05 | 2017-05-11 | Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi | Pharmaceutical compositions of imatinib |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI505828B (zh) * | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產(第二)有限公司 | 新穎醫藥組成物 |
CN102552268A (zh) * | 2010-12-23 | 2012-07-11 | 天津泰普药品科技发展有限公司 | 一种含有α晶型甲磺酸伊马替尼的药物制剂 |
PL394169A1 (pl) | 2011-03-09 | 2012-09-10 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania |
EA017781B1 (ru) * | 2011-05-24 | 2013-03-29 | Тева Канада Лимитед | Покрытая пленочной оболочкой таблетка, содержащая иматиниб мезилат, и способ ее получения |
EA026665B1 (ru) | 2011-11-24 | 2017-05-31 | Имунекс Фарма Илак Санайи Ве Тикарет А.С. | Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением |
EP2817030A1 (en) | 2012-02-21 | 2014-12-31 | Ranbaxy Laboratories Limited | Stable dosage forms of imatinib mesylate |
CN102600146B (zh) * | 2012-04-11 | 2014-10-08 | 兆科药业(合肥)有限公司 | 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法 |
JP5928159B2 (ja) * | 2012-05-28 | 2016-06-01 | ニプロ株式会社 | 医薬組成物 |
KR101520792B1 (ko) * | 2013-04-10 | 2015-05-15 | 보령제약 주식회사 | 고부하 이매티닙 정제 |
EP2803353B1 (en) * | 2013-05-14 | 2018-05-23 | Hetero Research Foundation | Compositions of Imatinib |
EP3019159A4 (en) * | 2013-07-09 | 2017-01-18 | Shilpa Medicare Limited | Oral pharmaceutical compositions comprising imatinib mesylate |
WO2019016673A2 (en) * | 2017-07-20 | 2019-01-24 | Kashiv Pharma Llc | STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB |
US20220175774A1 (en) * | 2020-12-07 | 2022-06-09 | Alembic Pharmaceuticals Limited | Bioavailable Oral Dosage Form Of Tyrosine-Kinase Inhibitor |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US20030215502A1 (en) * | 2002-03-20 | 2003-11-20 | Elan Pharma International Limited | Fast dissolving dosage forms having reduced friability |
US6716453B1 (en) * | 1999-05-20 | 2004-04-06 | Verion, Inc. | Method for increasing the active loading of compressible composition forms |
US6894051B1 (en) * | 1997-07-18 | 2005-05-17 | Novartis Ag | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
US20060275372A1 (en) * | 2005-06-03 | 2006-12-07 | Elan Pharma International Limited | Nanoparticulate imatinib mesylate formulations |
US20070036850A1 (en) * | 2005-08-15 | 2007-02-15 | Siegfried Generics International Ag | Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound |
US7329661B2 (en) * | 2000-09-13 | 2008-02-12 | Novartis Ag | N-phenyl-3-pyrimidine-amine derivatives |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4086945B2 (ja) * | 1996-12-10 | 2008-05-14 | カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ | 非毒性V.Cholerae株の単離法およびその株由来のコレラワクチンの製造法 |
ITMI992711A1 (it) | 1999-12-27 | 2001-06-27 | Novartis Ag | Composti organici |
US6720003B2 (en) * | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
GB0201508D0 (en) | 2002-01-23 | 2002-03-13 | Novartis Ag | Organic compounds |
GB0202873D0 (en) | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
JP4500679B2 (ja) | 2002-07-29 | 2010-07-14 | アルザ・コーポレーシヨン | パリペリドンを制御送達する方法および投薬形態物 |
EP1558751A4 (en) | 2002-09-16 | 2007-08-22 | Plexxikon Inc | CRYSTALLINE STRUCTURE OF PROTEIN KINASE PIM-1 |
GB2398565A (en) | 2003-02-18 | 2004-08-25 | Cipla Ltd | Imatinib preparation and salts |
WO2004108067A2 (en) | 2003-04-03 | 2004-12-16 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
AU2003232650A1 (en) | 2003-05-06 | 2004-11-26 | Il Yang Pharm Co., Ltd. | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof |
AU2003237596A1 (en) * | 2003-06-02 | 2005-01-21 | Hetero Drugs Limited | Novel polymorphs of imatinib mesylate |
AU2003242988A1 (en) | 2003-06-06 | 2005-01-04 | Adibhatla Kali Sathya Bhujanga Rao | Process for the preparation of the anti-cancer drug imatinib and its analogues |
WO2005051350A2 (en) | 2003-10-28 | 2005-06-09 | Torrent Pharmaceuticals Limited | Water dispersible tablet |
EP1776089A2 (en) | 2003-12-31 | 2007-04-25 | Actavis Group hf | Donepezil formulations |
AR047530A1 (es) | 2004-02-04 | 2006-01-25 | Novartis Ag | Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida |
EP1720853B2 (en) * | 2004-02-11 | 2023-06-28 | Natco Pharma Limited | Pharmaceutical compositions of the 2 crystalline form of imatinib mesylate for use in the treatment of chronic myelogenous leukemia |
UA84462C2 (ru) * | 2004-04-02 | 2008-10-27 | Институт Фармацевтични | Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой |
NZ552841A (en) | 2004-08-04 | 2009-07-31 | Alza Corp | Controlled release dosage form comprising two layers, wherein the delay layer is substanially free of non-microencapsulated drug |
US20080187575A1 (en) | 2004-08-27 | 2008-08-07 | Bert Klebl | Pyrimidine Derivatives |
US8269003B2 (en) * | 2004-09-02 | 2012-09-18 | Cipla Limited | Stable crystal form of imatinib mesylate and process for the preparation thereof |
WO2006040779A2 (en) * | 2004-10-11 | 2006-04-20 | Natco Pharma Limited | Controlled release gastric floating matrix formulation containing imatinib |
WO2006048890A1 (en) * | 2004-11-04 | 2006-05-11 | Sun Pharmaceutical Industries Limited | Imatinib mesylate crystal form and process for preparation thereof |
WO2006054314A1 (en) | 2004-11-17 | 2006-05-26 | Natco Pharma Limited | Polymorphic forms of imatinib mesylate |
US20060189635A1 (en) | 2005-02-04 | 2006-08-24 | Michelle Kramer | Enhanced efficacy benzisoxazole derivative dosage forms and methods |
MY148074A (en) | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
UY29766A1 (es) * | 2005-08-26 | 2007-03-30 | Novartis Ag | Formas cristalinas delta y épsilon de mesilato de imatinib |
CA2824301C (en) | 2005-11-25 | 2016-01-12 | Novartis Ag | F, g, h, i and k crystal forms of imatinib mesylate |
MXPA06007070A (es) | 2006-03-24 | 2007-09-24 | Univ Kyushu | Compuestos organicos. |
EP2829538A1 (en) * | 2006-04-27 | 2015-01-28 | Sicor, Inc. | Polymorphic form of imatinib mesylate and process for its preparation |
US7977348B2 (en) * | 2006-04-27 | 2011-07-12 | Sicor Inc. | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α |
US20060223817A1 (en) * | 2006-05-15 | 2006-10-05 | Chemagis Ltd. | Crystalline imatinib base and production process therefor |
EP2076507A2 (en) * | 2006-10-26 | 2009-07-08 | Sicor, Inc. | Imatinib base, and imatinib mesylate and processes for preparation thereof |
US7550591B2 (en) * | 2007-05-02 | 2009-06-23 | Chemagis Ltd. | Imatinib production process |
PT2305263E (pt) * | 2007-06-07 | 2012-10-22 | Novartis Ag | Formas amorfas estabilizadas de mesilato de imatinib |
-
2008
- 2008-09-25 BR BRPI0817946 patent/BRPI0817946A2/pt not_active IP Right Cessation
- 2008-09-25 WO PCT/US2008/077750 patent/WO2009042809A1/en active Application Filing
- 2008-09-25 US US12/238,314 patent/US20090087489A1/en not_active Abandoned
- 2008-09-25 RU RU2010110982/15A patent/RU2470641C2/ru not_active IP Right Cessation
- 2008-09-25 MX MX2010003200A patent/MX2010003200A/es unknown
- 2008-09-25 US US12/238,328 patent/US8414918B2/en active Active
- 2008-09-25 JP JP2010526074A patent/JP2010540465A/ja active Pending
- 2008-09-25 KR KR1020107006512A patent/KR101041203B1/ko not_active IP Right Cessation
- 2008-09-25 CA CA2700844A patent/CA2700844A1/en not_active Abandoned
- 2008-09-25 EP EP08834562A patent/EP2081556A1/en not_active Withdrawn
- 2008-09-25 EP EP08834185A patent/EP2086520A1/en not_active Withdrawn
- 2008-09-25 WO PCT/US2008/077743 patent/WO2009042803A1/en active Application Filing
-
2011
- 2011-03-14 JP JP2011055998A patent/JP2011140508A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US6894051B1 (en) * | 1997-07-18 | 2005-05-17 | Novartis Ag | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
US6716453B1 (en) * | 1999-05-20 | 2004-04-06 | Verion, Inc. | Method for increasing the active loading of compressible composition forms |
US7329661B2 (en) * | 2000-09-13 | 2008-02-12 | Novartis Ag | N-phenyl-3-pyrimidine-amine derivatives |
US20030215502A1 (en) * | 2002-03-20 | 2003-11-20 | Elan Pharma International Limited | Fast dissolving dosage forms having reduced friability |
US20060275372A1 (en) * | 2005-06-03 | 2006-12-07 | Elan Pharma International Limited | Nanoparticulate imatinib mesylate formulations |
US20070036850A1 (en) * | 2005-08-15 | 2007-02-15 | Siegfried Generics International Ag | Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011160798A1 (en) * | 2010-06-21 | 2011-12-29 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof |
EA029416B1 (ru) * | 2010-06-21 | 2018-03-30 | Заклады Фармацеутицне Польфарма Са | Таблетка, содержащая иматиниб или его фармацевтически приемлемую соль, и способ ее получения |
WO2012087256A2 (en) * | 2010-12-20 | 2012-06-28 | Mahmut Bilgic | Pharmaceutical capsule formulations |
WO2012087255A3 (en) * | 2010-12-20 | 2012-08-16 | Mahmut Bilgic | Pharmaceutical formulations comprising imatinib |
WO2012087256A3 (en) * | 2010-12-20 | 2012-09-27 | Mahmut Bilgic | Pharmaceutical capsule formulations |
WO2017078647A1 (en) | 2015-11-05 | 2017-05-11 | Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi | Pharmaceutical compositions of imatinib |
Also Published As
Publication number | Publication date |
---|---|
MX2010003200A (es) | 2010-04-30 |
JP2010540465A (ja) | 2010-12-24 |
CA2700844A1 (en) | 2009-04-02 |
EP2086520A1 (en) | 2009-08-12 |
EP2081556A1 (en) | 2009-07-29 |
KR20100054843A (ko) | 2010-05-25 |
RU2470641C2 (ru) | 2012-12-27 |
WO2009042809A1 (en) | 2009-04-02 |
RU2010110982A (ru) | 2011-09-27 |
US20090092669A1 (en) | 2009-04-09 |
JP2011140508A (ja) | 2011-07-21 |
KR101041203B1 (ko) | 2011-06-13 |
BRPI0817946A2 (pt) | 2015-05-05 |
US8414918B2 (en) | 2013-04-09 |
WO2009042809A8 (en) | 2009-07-02 |
WO2009042803A1 (en) | 2009-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090087489A1 (en) | Imatinib compositions | |
US11883403B2 (en) | Pharmaceutical compositions comprising Afatinib | |
US8877238B2 (en) | Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound | |
US20130344146A1 (en) | Dry formulations of aripiprazole | |
US20050191350A1 (en) | Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof | |
US20150335653A1 (en) | Pharmaceutical compositions of linezolid | |
US20080311202A1 (en) | Pharmaceutical Composition Containing Donepezil Hydrochloride, Tablets Produced Therefrom and Methods for Producing the Same | |
AU2016268477B2 (en) | Pharmaceutical compositions | |
US20130085145A1 (en) | Imatinib mesilate pharmaceutical tablet | |
US20090030057A1 (en) | Pharmaceutical composition of telmisartan | |
EP2803353B1 (en) | Compositions of Imatinib | |
WO2024115680A1 (en) | Ribociclib salts and formulations thereof | |
WO2022115057A1 (en) | Improved manufacturing method for the formulations comprising vortioxetine hbr butanol solvate form h |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TEVA PHARMACEUTICALS USA, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF RIGHS IN BARBADOS;ASSIGNOR:TEVA PHARMACEUTICAL INDUSTRIES LTD.;REEL/FRAME:021970/0812 Effective date: 20081118 |
|
AS | Assignment |
Owner name: TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GERBER, BELLA;DOANI, ZVIKA;REEL/FRAME:021970/0818 Effective date: 20081026 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |